Aridis Pharmaceuticals Stock Fundamentals
Aridis Pharmaceuticals fundamentals help investors to digest information that contributes to Aridis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aridis Pink Sheet. The fundamental analysis module provides a way to measure Aridis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aridis Pharmaceuticals pink sheet.
Aridis |
Aridis Pharmaceuticals Company Shares Owned By Insiders Analysis
Aridis Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Aridis Pharmaceuticals Shares Owned By Insiders | 31.53 % |
Most of Aridis Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aridis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 31.53% of Aridis Pharmaceuticals are shares owned by insiders. This is 107.71% higher than that of the Biotechnology sector and 122.36% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Aridis Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aridis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aridis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aridis Pharmaceuticals competition to find correlations between indicators driving Aridis Pharmaceuticals's intrinsic value. More Info.Aridis Pharmaceuticals is rated below average in return on asset category among its peers. It is rated third in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aridis Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Aridis Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aridis Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics of similar companies.Aridis Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Aridis Fundamentals
| Return On Asset | -1.08 | ||||
| Operating Margin | (9.58) % | ||||
| Current Valuation | 12.11 M | ||||
| Shares Outstanding | 36.21 M | ||||
| Shares Owned By Insiders | 31.53 % | ||||
| Shares Owned By Institutions | 11.60 % | ||||
| Number Of Shares Shorted | 2 M | ||||
| Price To Earning | (1.41) X | ||||
| Price To Book | 5.40 X | ||||
| Price To Sales | 7.33 X | ||||
| Gross Profit | (22.61 M) | ||||
| EBITDA | (29.51 M) | ||||
| Net Income | (30.37 M) | ||||
| Cash And Equivalents | 6.32 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 6.13 M | ||||
| Debt To Equity | (0.18) % | ||||
| Current Ratio | 0.41 X | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (29.13 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (1.15) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 13.24 M | ||||
| Total Asset | 14.7 M | ||||
| Retained Earnings | (195.67 M) | ||||
| Working Capital | (25.27 M) | ||||
| Current Asset | 27.39 M | ||||
| Current Liabilities | 3.06 M | ||||
| Z Score | -26.03 | ||||
| Net Asset | 14.7 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |